

Miguel H Vicco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4049983/publications.pdf>

Version: 2024-02-01

26
papers

205
citations

1163117

8
h-index

1058476

14
g-index

27
all docs

27
docs citations

27
times ranked

295
citing authors

#	ARTICLE	IF	CITATIONS
1	Congenital chagas disease: Development and assessment of a specific IgM capture-based assay for diagnosis of transmission. <i>Acta Tropica</i> , 2021, 213, 105738.	2.0	2
2	Functional Autoreactive Anti-Î²2 Adrenergic Antibodies May Contribute to Insulin Resistance Profile in Patients with Chronic Chagas Disease. <i>Pathogens</i> , 2021, 10, 378.	2.8	0
3	Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2021, 45, 1.	1.1	4
4	Increased epicardial adipose tissue thickness associated with increased metabolic risk and the presence of heart failure in patients with Chronic Chagas disease. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 1054-1060.	1.8	1
5	The importance of being scientifically cautious when criticizing the administration of vaccines: â€˜retractedâ€™ post truth. <i>Immunotherapy</i> , 2019, 11, 7-9.	2.0	2
6	ObjeciÃ³n de conciencia como necesidad legal: una mirada desde el aborto. <i>Revista Bioetica</i> , 2019, 27, 528-534.	0.2	1
7	Development and assessment of an improved recombinant multiepitope antigen-based immunoassay to diagnose chronic Chagas disease. <i>Parasitology</i> , 2018, 145, 1594-1599.	1.5	20
8	Trans-sialidase overcomes many antigens to be used as a vaccine candidate against <i>Trypanosoma cruzi</i> . <i>Immunotherapy</i> , 2017, 9, 555-565.	2.0	16
9	Trans-sialidase-based vaccine candidate protects against <i>Trypanosoma cruzi</i> infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype. <i>Oncotarget</i> , 2017, 8, 58003-58020.	1.8	23
10	The potential influence of atherogenic dyslipidemia on the severity of chronic Chagas heart disease. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2016, 62, 45-47.	0.7	1
11	Chronic Chagas disease: can prophylaxis and therapeutic vaccines crack this â€˜hard nutâ€™?. <i>Immunotherapy</i> , 2016, 8, 99-101.	2.0	1
12	Combined analysis of cross-reacting antibodies antiâ€˜Î²1<sc>AR</sc> and antiâ€˜B13 in advanced stages of Chagas heart disease. <i>Tropical Medicine and International Health</i> , 2016, 21, 1545-1551.	2.3	5
13	Antibody profiles induced by <i>Trypanosoma cruzi</i> in chagasic patients with previous or current exposure to mycobacteria. <i>Pathogens and Disease</i> , 2016, 74, ftw109.	2.0	1
14	IgG Autoantibodies Induced by T. cruzi During Pregnancy: Correlation with Gravidity Complications and Early Outcome Assessment of the Newborns. <i>Maternal and Child Health Journal</i> , 2016, 20, 2057-2064.	1.5	1
15	In-hospital mortality risk factors in patients with ascites due to cirrhosis. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2015, 61, 35-39.	0.7	8
16	In-hospital mortality risk factors in community acquired pneumonia: evaluation of immunocompetent adult patients without comorbidities. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2015, 61, 144-149.	0.7	6
17	Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. <i>Vaccine</i> , 2015, 33, 1274-1283.	3.8	38
18	Preparation and Characterization of a Staphylococcus aureus Capsular Polysaccharide-Protein Conjugate Prepared by a Low Cost Technique: a Proof-of-Concept Study. <i>Applied Biochemistry and Biotechnology</i> , 2015, 175, 141-154.	2.9	4

#	ARTICLE	IF	CITATIONS
19	Chagas disease, a risk factor for high blood pressure. <i>Blood Pressure</i> , 2014, 23, 345-348.	1.5	8
20	β1-Selective Adrenoceptor Antagonists Increase Plasma Levels of Anti-p21 Antibodies and Decrease Cardiac Involvement in Chronic Progressive Chagas Heart Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, 332-337.	1.7	15
21	Non-uremic calciphylaxis and Chagas disease. <i>Revista Clinica Espanola</i> , 2014, 214, e55-e57.	0.6	2
22	Decreased level of antibodies and cardiac involvement in patients with chronic Chagas heart disease vaccinated with BCG. <i>Medical Microbiology and Immunology</i> , 2014, 203, 133-139.	4.8	10
23	Chagas disease reactivation in a patient non-Hodgkin's lymphoma. <i>Revista Clinica Espanola</i> , 2014, 214, e83-e85.	0.6	4
24	Valoración de anticuerpos con reactividad cruzada patógeno-humano en pacientes con diferentes estadios de cardiopatía chagásica crónica. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 791-796.	1.2	14
25	Assessment of Cross-reactive Host-pathogen Antibodies in Patients With Different Stages of Chronic Chagas Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 791-796.	0.6	11
26	Chronic Chagas disease with cardiodigestive involvement and the TcVI infective form of <i>Trypanosoma cruzi</i> . A case report. <i>Parasitology International</i> , 2012, 61, 735-737.	1.3	7